(Q43037502)

English

Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin

scientific article published in January 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

0 references

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Masashi Namikawa

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Satoru Kakizaki

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yutaka Yata

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yuichi Yamazaki

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Norio Horiguchi

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ken Sato

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hitoshi Takagi

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Masatomo Mori

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

69-75

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hepatitis C: the clinical spectrum of the disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Clinical characteristics of null responders to Peg-IFNα2b/ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Detection and quantitation of HCV RNA using real-time PCR after automated sample processing.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

A high-throughput SNP typing system for genome-wide association studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06802.X

21 January 2018

Identifiers

10.1111/J.1440-1746.2011.06802.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43037502&oldid=1978288457"